氟喹诺酮超常规剂量治疗呼吸道感染的药效学变化和耐药状况

摘要

目的 探讨氟喹诺酮超常规剂量治疗呼吸道感染的药效学变化和耐药状况.方法 回顾性分析120例呼吸道感染患者的临床资料,根据患者服用氟喹诺酮类药物剂量的不同分为超常规组(研究组)和常规组(对照组),分析2组患者药效学变化和耐药状况.结果 2组患者在年龄、性别、体质量和治疗时间上比较,差异无统计学意义(P＞0.05),研究组治疗费用显著高于对照组(P＜0.01).研究组中左氧氟沙星、莫西沙星和环丙沙星的最大血药浓度(Cmax)显著高于对照组,达峰时间(tmax)显著低于对照组(P＜0.05).2组药物半衰期(T1/2)无显著差异(P＞0.05).研究组患者的总体显效率显著高于对照组(P＜0.05),研究组的耐药比例显著高于对照组(P＜0.05).结论 超常规使用氟喹诺酮类药物对于治疗呼吸道感染疾病有较好的临床治疗效果,但其耐药性更高,临床上应当合理控制用量.%Objective To explore the pharmacodynamics change and drug resistance of hypernormal dose fluoroquinolone in the treatment of patients with respiratory tract infection.Methods Clinical data of 120 patients with respiratory tract infection was analyzed retrospectively,and they were divided into hypernormal group (study group) and routine group (control group) according to fluoroquinolones dose.Pharmacodynamic change and drug resistance were analyzed between two groups.Results There were no significant differences in age,sex,weight and treatment time between the two groups (P ＞ 0.05),but the treatment cost in the study group was significantly higher than the control group (P ＜ 0.01).The maximum plasma concentrations (Cmax) of levofloxacin,moxifloxacin and ciprofloxacin were significantly higher than the control group,the peak time (Tmax) was significantly lower than the control group (P ＜ 0.05).Drug half-life (T1/2) showed no significant difference between two groups (P ＞ 0.05).The overall effective rate of the study group was significantly higher than that of the control group (P ＜ 0.05),and ratio of drug resistance was significantly higher than the control group (P ＜ 0.05).Conclusion Application of hypernormal dose fluoroquinolone is effective in treatment of patients with respiratory tract infection,but its drug resistance is higher,so the clinical dosage should be reasonable controlled.